- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- PFIZER LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Pfizer Quarterly Results 
(PFIZ)
Here are the latest quarterly results of Pfizer. For more details, see the Pfizer financial fact sheet and Pfizer share price and chart. For a sector overview, read our pharmaceuticals sector report.
Pfizer Quarterly Results
| No. of Mths Qtr. Ending |
3
Mar-17* |
3
Jun-17 |
3
Sep-17 |
3
Dec-17 |
3
Mar-18 |
3
Jun-18 |
3
Sep-18 |
3
Dec-18 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 4,532 | 4,326 | 5,711 | 4,565 | 5,200 | 5,123 | 5,197 | 5,138 | |
| Other income | Rs m | 288 | 273 | 237 | 321 | 312 | 305 | 371 | 644 | |
| Turnover | Rs m | 4,820 | 4,599 | 5,948 | 4,886 | 5,512 | 5,428 | 5,568 | 5,781 | |
| Expenses | Rs m | 3,585 | 3,559 | 4,039 | 3,386 | 3,813 | 3,822 | 3,900 | 3,595 | |
| Gross profit | Rs m | 947 | 767 | 1,672 | 1,179 | 1,385 | 1,301 | 1,298 | 1,543 | |
| Depreciation | Rs m | 165 | 152 | 160 | 177 | 173 | 183 | 177 | 178 | |
| Interest | Rs m | 1 | 2 | 2 | 2 | -1 | 2 | 2 | 3 | |
| Profit before tax | Rs m | 1,069 | 885 | 1,748 | 1,321 | 1,525 | 1,422 | 1,489 | 2,006 | |
| Tax | Rs m | 388 | 314 | 636 | 448 | 480 | 504 | 531 | 687 | |
| Profit after tax | Rs m | 680 | 572 | 1,112 | 872 | 1,045 | 918 | 958 | 1,319 | |
| Gross profit margin | % | 20.9 | 17.7 | 29.3 | 25.8 | 26.6 | 25.4 | 25.0 | 30.0 | |
| Effective tax rate | % | 36.3 | 35.4 | 36.4 | 33.9 | 31.5 | 35.4 | 35.7 | 34.2 | |
| Net profit margin | % | 15.0 | 13.2 | 19.5 | 19.1 | 20.1 | 17.9 | 18.4 | 25.7 | |
| Diluted EPS | Rs | 14.9 | 12.5 | 24.3 | 19.1 | 22.8 | 20.1 | 20.9 | 28.8 | |
| Diluted EPS (TTM) | Rs | 73.6 | 68.6 | 65.3 | 70.7 | 78.7 | 86.3 | 82.9 | 92.7 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Pfizer 3QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: SANOFI INDIA ORCHID PHARMA LTD GLENMARK PHARMA SUVEN LIFE NATCO PHARMA
Compare PFIZER With: SANOFI INDIA ORCHID PHARMA LTD GLENMARK PHARMA SUVEN LIFE NATCO PHARMA
Compare PFIZER With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Opens Strong; Metal & Energy Stocks Lead(09:30 am)
Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.7% while the Hang Seng is up 0.9%.
Views on news
PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)
Jan 25, 2019 | Updated on Jan 25, 2019For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.
PFIZER 2017-18 Annual Report Analysis (Annual Result Update)
Jan 1, 2019 | Updated on Jan 1, 2019Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.
PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)
Nov 15, 2018 | Updated on Nov 15, 2018For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)
Feb 7, 2019Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...
The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)
Feb 13, 2019The real estate sector is ready to make a comeback. This is the stock to consider buying.
How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)
Feb 8, 2019This is the trick to following super investors and not losing money.
Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)
Feb 14, 2019Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)
Feb 14, 2019During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.
More|
| |
PFIZER SHARE PRICE
Feb 20, 2019 11:19 AM
TRACK PFIZER
- Track your investment in PFIZER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON PFIZER
PFIZER 5-YR ANALYSIS
COMPARE PFIZER WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.